- Home
- CRF vs CSTL Comparison
CRF vs CSTL Comparison
Compare CRF & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRF
- CSTL
- Stock Information
- Founded
- CRF 1973
- CSTL 2007
- Country
- CRF United States
- CSTL United States
- Employees
- CRF N/A
- CSTL N/A
- Industry
- CRF Finance/Investors Services
- CSTL Medical Specialities
- Sector
- CRF Finance
- CSTL Health Care
- Exchange
- CRF Nasdaq
- CSTL Nasdaq
- Market Cap
- CRF 926.5M
- CSTL 946.1M
- IPO Year
- CRF N/A
- CSTL 2019
- Fundamental
- Price
- CRF $9.01
- CSTL $29.81
- Analyst Decision
- CRF
- CSTL Strong Buy
- Analyst Count
- CRF 0
- CSTL 7
- Target Price
- CRF N/A
- CSTL $37.57
- AVG Volume (30 Days)
- CRF 620.5K
- CSTL 457.0K
- Earning Date
- CRF 01-01-0001
- CSTL 11-04-2024
- Dividend Yield
- CRF 17.97%
- CSTL N/A
- EPS Growth
- CRF N/A
- CSTL N/A
- EPS
- CRF N/A
- CSTL 0.21
- Revenue
- CRF N/A
- CSTL $311,878,000.00
- Revenue This Year
- CRF N/A
- CSTL $49.05
- Revenue Next Year
- CRF N/A
- CSTL N/A
- P/E Ratio
- CRF N/A
- CSTL $143.32
- Revenue Growth
- CRF N/A
- CSTL 62.43
- 52 Week Low
- CRF $6.05
- CSTL $16.97
- 52 Week High
- CRF $8.56
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- CRF 66.45
- CSTL 45.16
- Support Level
- CRF $8.62
- CSTL $27.24
- Resistance Level
- CRF $9.25
- CSTL $29.02
- Average True Range (ATR)
- CRF 0.16
- CSTL 1.93
- MACD
- CRF -0.00
- CSTL -0.46
- Stochastic Oscillator
- CRF 72.59
- CSTL 29.88
About CRF Cornerstone Total Return Fund Inc. (The)
Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology; Health Care; Financials; Communication Services; Consumer Discretionary; Industrials; Exchange-Traded Funds; Utilities; Energy; Real Estate and others.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.